
ANRO Stock Forecast & Price Target
ANRO Analyst Ratings
Bulls say
Alto Neuroscience is poised for future success with a solid cash runway through 2029 and promising clinical assets targeting major depressive disorders and schizophrenia. The company has demonstrated resilience in addressing eligibility and compliance issues with key pipeline updates, positioning it for potential regulatory filings as early as 2028. With a differentiated approach to identifying best responders and a strong focus on trial-quality controls, ANRO has the potential to make a significant impact in the field of personalized psychiatry.
Bears say
Alto Neuroscience is currently a clinical-stage biopharmaceutical company with a focus on developing personalized treatments utilizing biomarkers for CNS disorders. However, the company's pipeline products have shown mixed results in clinical trials and their approach to precision medicine is still unproven. In addition, the company relies heavily on third parties for drug supply and manufacturing, as well as conducting preclinical studies and clinical trials, which poses risks to the company's success. The company also faces significant financial risks and may need to raise additional capital which could result in share dilution for shareholders. Overall, the company's current status as a development stage company and its unproven approach to precision medicine make for a negative outlook on its stock.
This aggregate rating is based on analysts' research of Alto Neuroscience Inc and is not a guaranteed prediction by Public.com or investment advice.
ANRO Analyst Forecast & Price Prediction
Start investing in ANRO
Order type
Buy in
Order amount
Est. shares
0 shares